Glucagonlike Peptide 1 Receptor Agonists

GLP-1 receptor agonists are also called:

Incretin mimetics

The prototype GLP-1 receptor agonist is:

Exenatide

GLP-1 receptor agonists act by:

Stimulating insulin secretion post-meal

GLP-1 receptor agonists may:

Cause weight loss

Exenatide is administered:

Subcutaneous injection

Exenatide dosing should be:

6 hours apart

Common adverse effect of exenatide:

Nausea

Exenatide slows:

Gastric emptying

A rare but serious adverse effect:

Pancreatitis

GLP-1 RAs are used in:

Type 2 DM

Incretin mimetics can be combined with:

Metformin

Contraindication to exenatide:

Family hx of thyroid carcinoma

GLP-1 receptor agonists should be avoided during:

Pregnancy

A patient should skip exenatide if:

Skipping a meal

Exenatide is excreted via:

Urine

A patient is at increased risk of pancreatitis if they report:

Severe abdominal pain

GLP-1 agonists decrease:

Glucagon production

Patients should store exenatide:

In the refrigerator

Oral drug absorption may be:

Delayed by exenatide

BLACK BOX WARNING includes:

C-cell thyroid cancer

Other GLP-1 RAs include:

Dulaglutide, liraglutide, semaglutide

GLP-1 receptor agonists improve:

Postprandial glucose control

GLP-1 agonists act by:

Increasing insulin in response to meals

Liver injury risk mandates monitoring of:

AST/ALT

Semaglutide must be stopped:

2 months before planned pregnancy

GLP-1 receptor agonists are NOT approved in:

Type 1 DM

Exenatide peak effect:

2 hours

Patients taking exenatide should be taught:

Signs of hypoglycemia

Exenatide delays:

Gastric emptying

Main advantage over insulin:

Weight loss

Contraindication for semaglutide:

Pregnancy

GLP-1 RAs may be given:

Subcutaneously

Dosing for exenatide if forgotten:

Do not take after meal

Injection sites for exenatide:

Abdomen, thigh, arm

Serious side effect of GLP-1 RAs:

Pancreatitis